血清Cyfra21-1、CEA及影像学变化早期诊断肺癌复发与转移的研究进展

Research Progress of Serum Cyfra21-1,CEA and Imaging Changes in Early Diagnosis of Recurrence and Metastasis of Lung Cancer

肺癌是威胁人类健康最主要的疾病之一,早期判断是否复发转移,是摆在医务人员面前的一项艰巨的任务。影像学检查是目前诊断肺癌主要手段的依据,能观察病变所在位置,明确肺癌分期,对肺癌的定性和定位具有重要意义,但此时往往已非早期。肿瘤标志物对肺癌的发展及预后的评估价值已被认可,但迄今尚未发现对各种肺癌均有高敏感性和高特异性的标志物,血清Cyfra21-1、癌胚抗原是常用于肺癌诊断的肿瘤标志物,两者联检可提高检测肺癌复发与转移的灵敏度和总符合率,却仍然存在一定的假阳性率、假阴性率,动态检测、加强与影像学密切结合研究,可望取长补短,进一步提高肺癌早期复发与转移诊断的灵敏度和准确率。

Lung cancer is one of the major diseases threatening human health,and early judgment of recurrence and metastasis is an arduous task facing medical personnel.Imaging examination is currently the major diagnosis of lung cancer,which can observe pathological changes in position,clarify lung cancer staging,thus is important for qualitative and localization of lung cancer,but often has already passed early stage.The assessment value of development of tumor markers for lung cancer and prognosis has been recognized,but so far high sensitivity and high specific markers for various lung cancer have not been found;serum Cyfra21-1 and CEA are markers for lung cancer,and joint check can improve the sensitivity and total coincidence rate for detection of lung cancer recurrence and metastasis,though a certain fake positive rate and fake negative rate still exist;dynamic detection,and strengthening research closely combined with imaging is expected to complement each other,and further improve the sensitivity and accuracy of early diagnosis of recurrence and metastasis of lung cancer.